

**THE FOLLOWING DRUGS WILL BE REVIEWED AT THE  
DRUG UTILIZATION REVIEW BOARD (DURB) MEETING**

**March 18, 2014**

**Georgia Department of Community Health**

**\*This list may change at any time. If a supplemental rebate class is not listed below, the class will be reviewed at the June 5<sup>th</sup> DURB Meeting and those manufacturers can present at the May Manufacturers' Forum. In addition, some of the supplemental rebate classes listed below will also be moved for review at the June 5<sup>th</sup> DURB meeting that will be determined in February; thus, these manufacturers can present at the February Manufacturers' Forum and will not need to present again at the May Manufacturers' Forum. Please check back frequently for updates.\***

**New Drugs for Review**

Actemra<sup>®</sup> Subcutaneous

Gilotrif<sup>™</sup>

Injectafer<sup>™</sup>

Mekinist<sup>™</sup>

Olysio<sup>™</sup>

Sovaldi<sup>™</sup>

Tafinlar<sup>®</sup>

Tivicay<sup>®</sup>

**Supplemental Rebate Classes for Review**

Amphetamines

Analgesics, Opioids

Androgens-Anabolics

Antianginal Agents

Anticoagulants

Antidementia Agents

Antidiabetics, Insulins

Antidiabetics, Non-insulins

Antidiarrheals
Antiemetics
Antihemophilics
Antihistamines
Antihyperlipidemics
Antihypertensives, Angiotensin Converting Enzyme (ACE) Inhibitors
Antihypertensives, Angiotensin Receptor Blockers (ARBs)
Antihypertensives, ARB/Calcium Channel Blocker (CCB) Combinations
Antihypertensives, Beta Blockers (BBs)
Antihypertensives, Direct Renin Inhibitors
Antiinfectives, Miscellaneous
Antiinflammatory, Nonsteroidal Antiinflammatory Drugs (NSAIDs)
Antiparkinson Agents
Antivirals, Antiretrovirals
Antivirals, Hepatitis Agents
Attention Deficit Hyperactivity Disorder (ADHD) Agents
Biologic Immunomodulators
Calcium Regulators, Osteoporosis
Cephalosporins, Oral
Corticosteroids, Oral
Cough and Cold Products
Dermatologics, Antiinflammatory

Dermatologics, Antipsoriatics
Dermatologics, Corticosteroids
Dermatologics, Scabicides/Pediculocides
Digestive Enzymes
Fibromyalgia Agents
Growth Hormones
Hematopoietic Agents
Inflammatory Bowel Agents
Inhaled Antibiotics for Cystic Fibrosis
Irritable Bowel Syndrome (IBS) Agents
Luteinizing-Hormone-Releasing Hormone (LHRH)/Gonadotropin-Releasing Hormone (GnRH) Agonist Analogs
Medical Devices for Inhaled Asthma Therapy
Migraine Agents
Multiple Sclerosis (MS) Agents
Multivitamins, Prenatal
Nasal Antiallergics
Nasal Decongestants
Nasal Steroids
Ophthalmics, Adrenergics
Ophthalmics, Antiallergics
Ophthalmics, Antiinfectives
Ophthalmics, Beta Blockers

Ophthalmics, Nonsteroidal Antiinflammatory Drugs (NSAIDs)
Ophthalmics, Prostaglandins
Ophthalmics, Steroids
Otic Antiinfectives
Phosphate Binders
Platelet Aggregate Inhibitors
Progestins
Smoking Deterrents
Ulcer Agents, Antispasmodics
Ulcer Agents, Miscellaneous
Ulcer Agents, Proton Pump Inhibitors (PPIs)
Urinary Antiinfectives
Urinary Antispasmodics
Urinary Prostatic Hypertrophy
Vaginal Antiinfectives
Vasopressors

**\*This list may change at any time. If a supplemental rebate class is not listed above, the class will be reviewed at the June 5<sup>th</sup> DURB Meeting and those manufacturers can present at the May Manufacturers' Forum. In addition, some of the supplemental rebate classes listed above will also be moved for review at the June 5<sup>th</sup> DURB meeting that will be determined in February; thus, these manufacturers can present at the February Manufacturers' Forum and will not need to present again at the May Manufacturers' Forum. Please check back frequently for updates.\***